The evaluation of intensive atorvastatin therapy for cardiovascular disease with sleep apnea disease and its mechanism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023231

Enrollment

Unknown

Registered

2019-05-17

Start date

2012-10-01

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease/

Interventions

2:20 mg atorvastatin

3:40-60 mg atorvastatin

1:conventional treatment except atorvastatin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients had myocardial infarction history and been implanted coronary stents, and others had a history of hypertension or hyperlipemia and all patients had a LVEF of= 50% without clinical evidence of heart failure

Exclusion criteria

Exclusion criteria: acute myocardial infarction (within 3 months), any increase in creatine kinase-MB (CK-MB), troponin I, or myoglobin above upper normal limit at the beginning of treatment, any double increase or more in liver enzymes, creatinine >3mg/dL, history of liver or muscle disease, or previous treatment with statins with allergy

Design outcomes

Primary

Measure	Time frame
AHI down to ˜ 50% or AHI <15 events/h;	—

Countries

China

Contacts

Public ContactCai Xu

The Affiliated Hospital, Ningbo University Medical School

caixu2000@hotmail.com+86 13701968612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026